Slide 1: Enhancing the Treatment of Retinal Disease
NASDAQ: OTLK outlooktherapeutics.com Enhancing the Treatment of Retinal Disease Corporate Presentation August 2026
Slide 2: Forward-looking statements
This presentation may contain or contains “forward-looking statements” about Outlook Therapeutics, Inc. (“Outlook Therapeutics” or the “Company”) based on management’s current expectations, which are subject to known and unknown uncertainties and risks. Words such as “can,” “could,” “expect,” “explo
Slide 3: Now FDA Approved!
Now FDA Approved! First and Only FDA-Approved Ophthalmic Formulation of Bevacizumab for the Treatment of Wet AMD Please visit lytenava.com for more information Please see the full Important Safety Information and Prescribing Information for complete safety details available at lytenava.com/ISI.
Slide 4: Consistent safety profile across clinical trials
Consistent safety profile across 5 clinical trials CONTRAINDICATIONS: • Ocular or periocular infections, Table 1. Common Adverse Reactions (≥1%)1 • Active intraocular inflammation, LYTENAVA Ranibizumab • Known hypersensitivity to bevacizumab products or any of the Adverse Reactions (n=601) (n=345) i
Slide 5: LYTENAVA: United States and Europe
LYTENAVA (bevacizumab-vikg; bevacizumab gamma) United States Received FDA Approval July 24, 2026 Commercial biopharmaceutical company U.S. Commercial Launch planned dedicated to developing therapies for the before calendar year-end 2026 preservation of vision 12 years of exclusivity under the Biolog
Slide 6: $8.5 Billion Total U.S. Anti-VEGF Retina Market
>$500 Million Annual Sales Base Case Before 2030 $8.5 Billion Total U.S. Anti-VEGF Retina Market1 Off-Label Repackaged Bevacizumab Predominantly Used in wAMD 1,2,3 Estimated Number of Select Retina Off-Label Repackaged Bevacizumab Injections in 2025 2 2.2M 1.4M wAMD Injections Injections related to
Slide 7: Advancing payer engagement and scaling commercial supply
Advancing payer engagement and scaling commercial supply Refreshing customer segmentation and targeting to maximize market adoption Planning HCPCS code submission in calendar year Q3 to support reimbursement strategy Building the commercial team while incorporating feedback from key stakeholders Upd
Slide 8: LYTENAVA Europe: Commercial Launch Underway
Europe LYTENAVA (bevacizumab gamma) Commercial Launch Underway Initial Launch Territories Include Germany, United Kingdom, Austria 8
Slide 9: Now Commercially Available in Germany, the United Kingdom, and Austria
First and Only Approved Ophthalmic Formulation of Bevacizumab for the Treatment of wet AMD Now Commercially Available in Germany, the United Kingdom, and Austria Positive NICE recommendation Received 10 years market exclusivity covering 31 countries Real-world evidence study initiated in Germa
Slide 10: $3.6 Billion Total European Anti-VEGF Retina Market
$3.6 Billion Total European Anti-VEGF Retina Market1 Off-Label Repackaged Bevacizumab is Already Being Used in Europe as First-Line Treatment for Wet AMD 2,3,4 1.52 Million Number of Treated Patients 3 Injections Annually of Total Anti-VEGF Injections Annually 8.3 Million Total Anti-VEGF Units 2,3,4
Slide 11: Growing Presence Across Europe
Growing Presence Across Europe Offices in London, Berlin, Amsterdam Netherlands Central hub for distribution across the region U.K. Germany Austria Netherlands Switzerland Now Available Now Available Now Available Target Launch 2026 Target Launch 2027 Initiating NE Submission Exclusive Commercial Di
Slide 12: Specialist Experience with Anti-VEGF Therapies
Specialist Experience with Anti-VEGF Therapies Bob Jahr Lawrence Jennifer Christopher Greg Laura Jennifer Chief Executive Kenyon Kissner, PhD Yonan, PhD DiPasquale Cantrell Couture Officer Chief Financial EVP Medical, SVP, Technical SVP, Head of VP, Corporate GCL/Global Head Officer Clinical and Ope
Slide 13: Targeting >$15.9 Billion Global Anti-VEGF Retina Market Opportunity
U.S.: Received FDA Approval with Commercial Launch Planned Before Calendar Year-end 2026 EU: Lytenava Commercially Available in Germany, the United Kingdom, and Austria Targeting >$15.9 Billion Global Anti-VEGF Retina Market Opportunity 1 Advancing Commercial Approved in European Union Infrastructur
Slide 14: Enhancing the Treatment of Retinal Disease
NASDAQ: OTLK outlooktherapeutics.com Enhancing the Treatment of Retinal Disease Investor Relations: JTC Team, LLC. otlk@jtcir.com 908-824-0775
Slide 15: Appendix: Clinical Data
Appendix Clinical Data 15
Slide 16: LYTENAVA demonstrates statistically significant improvement in visual acuity
LYTENAVA demonstrates statistically significant and clinically meaningful improvement in visual acuity • Demonstrated statistically significant ONS-5010 ranibizumab and clinically relevant evidence of 50 ONS-5010 ranibizumab Proportion of Subjects Gaining efficacy across primary and Characteristic ≥